ClinGen Hemoglobinopathy VCEP ACMG/AMP specifications for HBB and HBA2 variant interpretation in thalassemia
Abstract
Background: The ClinGen Hemoglobinopathy Variant Curation Expert Panel (VCEP) was established in 2019 to develop disease-specific adaptations of the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) sequence variant interpretation framework for hemoglobinopathies. This study describes the development, validation, and ClinGen approval of the first disease-specific ACMG/AMP specifications for autosomal recessive thalassemia related to HBB and HBA2, providing a standardized framework for globin gene variant interpretation. Methods: Disease-specific ACMG/AMP rule specifications were developed in accordance with ClinGen procedures and Variant Classification Working Group recommendations and evaluated through pilot curation of representative HBB and HBA2 variants using the ClinGen Variant Curation Interface (VCI), with independent biocurator assessment, expert review, and consensus approval. Results: A total of 34 disease-specific evidence specifications were developed across the two gene-disease pairs, encompassing 22 ACMG/AMP evidence criteria and one modification to the ACMG/AMP evidence-combining rules. Pilot application to 33 representative variants (20 HBB, 13 HBA2) demonstrated high concordance with established pathogenic and benign classifications while providing a standardized framework for resolving variants with conflicting or limited evidence. Following pilot validation, the specifications received ClinGen approval, and all curated variants with supporting evidence were disseminated through the ClinGen Evidence Repository (ERepo) and ClinVar. Conclusions: The ClinGen Hemoglobinopathy VCEP specifications provide the first ClinGen-approved disease-specific ACMG/AMP rule specifications for HBB and HBA2 variants related to thalassemia. These specifications establish a robust and transparent framework for harmonized globin variant interpretation and provide a foundation for sustained expert curation, continued refinement through emerging evidence, and expansion to additional hemoglobinopathy gene-disease pairs.
Related
- Variant Classification of a Non-Protein Coding Gene: ACMG/AMP Specifications for RMRP from the Clinical Genome Resource Severe Combined Immunodeficiency Disease Variant Curation Expert Panel
- Prevalence and clinical significance of α-globin gene subtypes in prenatal thalassemia screening: a focus on the -α3.7III variant in Sanya, Hainan, China
- Deep mutational scanning of CYP2C9, CYP2C19, and NUDT15 shows that pharmacogene variant interpretation requires assay-specific functional data
- Founder alleles and clonal hematopoiesis, not missing diversity, confound variant interpretation in an underrepresented population
- Germline Variants Absent from Global Reference Databases in Malawian DLBCL Patients: Implications for Variant Interpretation in African Genomic Medicine
BibTeX
@misc{stephanou2026clingen,
title = {{ClinGen Hemoglobinopathy VCEP ACMG/AMP specifications for HBB and HBA2 variant interpretation in thalassemia}},
author = {Coralea Stephanou and Irene Fylaktou and Hashim Halim-Fikri and Tamara T Koopmann and Landry E Nfonsam and Celeste Bento and Cornelis L Harteveld and Marina Kleanthous and Joanne Traeger-Synodinos and Kyriaki Michailidou and Thessalia Papasavva and Bin Alwi Zilfalil and Justyne E Ross and John S Waye and Carsten W Lederer and Petros Kountouris and ClinGen Hemoglobinopathy Variant Curation Expert Panel},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.30.26366794},
url = {https://www.medrxiv.org/content/10.64898/2026.10.30.26366794v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - ClinGen Hemoglobinopathy VCEP ACMG/AMP specifications for HBB and HBA2 variant interpretation in thalassemia
AU - Coralea Stephanou
AU - Irene Fylaktou
AU - Hashim Halim-Fikri
AU - Tamara T Koopmann
AU - Landry E Nfonsam
AU - Celeste Bento
AU - Cornelis L Harteveld
AU - Marina Kleanthous
AU - Joanne Traeger-Synodinos
AU - Kyriaki Michailidou
AU - Thessalia Papasavva
AU - Bin Alwi Zilfalil
AU - Justyne E Ross
AU - John S Waye
AU - Carsten W Lederer
AU - Petros Kountouris
AU - ClinGen Hemoglobinopathy Variant Curation Expert Panel
PY - 2026
DA - 2026/10/30
PB - medRxiv
DO - 10.64898/2026.10.30.26366794
UR - https://www.medrxiv.org/content/10.64898/2026.10.30.26366794v1
AB - Background: The ClinGen Hemoglobinopathy Variant Curation Expert Panel (VCEP) was established in 2019 to develop disease-specific adaptations of the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) sequence variant interpretation framework for hemoglobinopathies. This study describes the development, validation, and ClinGen approval of the first disease-specific ACMG/AMP specifications for autosomal recessive thalassemia related to HBB and HBA2, providing a standardized framework for globin gene variant interpretation. Methods: Disease-specific ACMG/AMP rule specifications were developed in accordance with ClinGen procedures and Variant Classification Working Group recommendations and evaluated through pilot curation of representative HBB and HBA2 variants using the ClinGen Variant Curation Interface (VCI), with independent biocurator assessment, expert review, and consensus approval. Results: A total of 34 disease-specific evidence specifications were developed across the two gene-disease pairs, encompassing 22 ACMG/AMP evidence criteria and one modification to the ACMG/AMP evidence-combining rules. Pilot application to 33 representative variants (20 HBB, 13 HBA2) demonstrated high concordance with established pathogenic and benign classifications while providing a standardized framework for resolving variants with conflicting or limited evidence. Following pilot validation, the specifications received ClinGen approval, and all curated variants with supporting evidence were disseminated through the ClinGen Evidence Repository (ERepo) and ClinVar. Conclusions: The ClinGen Hemoglobinopathy VCEP specifications provide the first ClinGen-approved disease-specific ACMG/AMP rule specifications for HBB and HBA2 variants related to thalassemia. These specifications establish a robust and transparent framework for harmonized globin variant interpretation and provide a foundation for sustained expert curation, continued refinement through emerging evidence, and expansion to additional hemoglobinopathy gene-disease pairs.
ER -